Communication

Nocodazole is a High-Affinity Ligand for the Cancer-Related Kinases ABL, c-KIT, BRAF, and MEK

  1. Prof. Hwangseo Park1,*,
  2. Seunghee Hong2,
  3. Prof. Sungwoo Hong2,*

Article first published online: 14 OCT 2011

DOI: 10.1002/cmdc.201100410

Issue

ChemMedChem

ChemMedChem

Volume 7, Issue 1, pages 53–56, January 2, 2012

Additional Information

How to Cite

Park, H., Hong, S. and Hong, S. (2012), Nocodazole is a High-Affinity Ligand for the Cancer-Related Kinases ABL, c-KIT, BRAF, and MEK. ChemMedChem, 7: 53–56. doi: 10.1002/cmdc.201100410

Author Information

  1. 1

    Department of Bioscience and Biotechnology, Sejong University, 98 Kunja-dong, Kwangjin-ku, Seoul 143-747 (Korea)

  2. 2

    Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Guseong-dong, Yuseong-gu, Daejeon 305-701 (Korea)

*Department of Bioscience and Biotechnology, Sejong University, 98 Kunja-dong, Kwangjin-ku, Seoul 143-747 (Korea)

Publication History

  1. Issue published online: 27 DEC 2011
  2. Article first published online: 14 OCT 2011
  3. Manuscript Revised: 1 OCT 2011
  4. Manuscript Received: 26 AUG 2011

Funded by

  • Korea Institute of Oriental Medicine. Grant Number: K11061
  • National Research Foundation of Korea. Grant Numbers: NRF-2011-0003609, 2011-0016436, 2011-0020322

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (758K)

Keywords:

  • ABL;
  • anticancer agents;
  • inhibitors;
  • kinases;
  • nocodazole
Thumbnail image of graphical abstract

New from old: Nocodazole displays high affinity for a set of cancer-related kinases, including ABL, c-KIT, BRAF, and MEK. These experimental and computational findings may provide insight into the design of new and potent inhibitors of common kinases based on the nocodazole scaffold.

View Full Article with Supporting Information (HTML) Get PDF (758K)